Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47


A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL, Kelly RJ, Coleman B, Gabrielson E, Rosner GL, Ettinger DS.

Oncologist. 2018 Feb 27. pii: theoncologist.2017-0465. doi: 10.1634/theoncologist.2017-0465. [Epub ahead of print]


A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164. Epub 2016 Sep 30.


Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH.

Cancer. 2016 Aug 1;122(15):2371-8. doi: 10.1002/cncr.30062. Epub 2016 May 10.


Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.

MacDiarmid JA, Langova V, Bailey D, Pattison ST, Pattison SL, Christensen N, Armstrong LR, Brahmbhatt VN, Smolarczyk K, Harrison MT, Costa M, Mugridge NB, Sedliarou I, Grimes NA, Kiss DL, Stillman B, Hann CL, Gallia GL, Graham RM, Brahmbhatt H.

PLoS One. 2016 Apr 6;11(4):e0151832. doi: 10.1371/journal.pone.0151832. eCollection 2016.


A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis.

Sun H, Luo L, Lal B, Ma X, Chen L, Hann CL, Fulton AM, Leahy DJ, Laterra J, Li M.

Nat Commun. 2016 Feb 4;7:10339. doi: 10.1038/ncomms10339.


Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.


Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT 3rd, Giaccone G.

J Clin Oncol. 2015 Dec 1;33(34):4106-11. doi: 10.1200/JCO.2015.63.7918. Epub 2015 Sep 8.


A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter CL, Johnson NW, Hann CL, Kruger RG.

Cancer Cell. 2015 Jul 13;28(1):57-69. doi: 10.1016/j.ccell.2015.06.002.


A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, Belani CP, Hann CL, Aggarwal C, Ramalingam SS.

Lung Cancer. 2015 Jul;89(1):66-70. doi: 10.1016/j.lungcan.2015.04.015. Epub 2015 May 8.


DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.

Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM.

Oncogene. 2015 Nov 26;34(48):5869-78. doi: 10.1038/onc.2015.38. Epub 2015 Mar 9.


Rapamycin rescues ABT-737 efficacy in small cell lung cancer.

Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL, Rudin CM, Hann CL.

Cancer Res. 2014 May 15;74(10):2846-56. doi: 10.1158/0008-5472.CAN-13-3460. Epub 2014 Mar 10.


Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.

Forde PM, Hooker CM, Boikos SA, Petrini I, Giaccone G, Rudin CM, Yang SC, Illei PB, Hann CL, Ettinger DS, Brahmer JR, Kelly RJ.

J Thorac Oncol. 2014 Mar;9(3):414-8. doi: 10.1097/JTO.0000000000000065.


Bisphosphonamidate clodronate prodrug exhibits selective cytotoxic activity against melanoma cell lines.

Webster MR, Kamat C, Connis N, Zhao M, Weeraratna AT, Rudek MA, Hann CL, Freel Meyers CL.

Mol Cancer Ther. 2014 Feb;13(2):297-306. doi: 10.1158/1535-7163.MCT-13-0315. Epub 2013 Dec 5.


Erlotinib inhibits growth of a patient-derived chordoma xenograft.

Siu IM, Ruzevick J, Zhao Q, Connis N, Jiao Y, Bettegowda C, Xia X, Burger PC, Hann CL, Gallia GL.

PLoS One. 2013 Nov 15;8(11):e78895. doi: 10.1371/journal.pone.0078895. eCollection 2013.


Tumor lysis syndrome in limited-stage small-cell lung cancer.

Boikos SA, Forde PM, Chatterjee S, Hann CL.

J Thorac Oncol. 2013 Jul;8(7):e61-2. doi: 10.1097/JTO.0b013e318286bb3b. No abstract available.


Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.

Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM.

J Natl Cancer Inst. 2013 Jul 17;105(14):1059-65. doi: 10.1093/jnci/djt130. Epub 2013 Jun 5.


Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.

Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO.

J Thorac Oncol. 2013 May;8(5):619-23. doi: 10.1097/JTO.0b013e31828c3950.


ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.

Zinn RL, Gardner EE, Marchionni L, Murphy SC, Dobromilskaya I, Hann CL, Rudin CM.

Mol Cancer Ther. 2013 Jun;12(6):1131-9. doi: 10.1158/1535-7163.MCT-12-0618. Epub 2013 Mar 20.


Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.

Zinn RL, Gardner EE, Dobromilskaya I, Murphy S, Marchionni L, Hann CL, Rudin CM.

Mol Cancer. 2013 Mar 2;12:16. doi: 10.1186/1476-4598-12-16.


Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo.

Kamat CD, Shmueli RB, Connis N, Rudin CM, Green JJ, Hann CL.

Mol Cancer Ther. 2013 Apr;12(4):405-15. doi: 10.1158/1535-7163.MCT-12-0956. Epub 2013 Jan 30.


Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L.

Clin Cancer Res. 2012 Jun 1;18(11):3163-9. doi: 10.1158/1078-0432.CCR-11-3090. Epub 2012 Apr 11.


Establishment and characterization of a primary human chordoma xenograft model.

Siu IM, Salmasi V, Orr BA, Zhao Q, Binder ZA, Tran C, Ishii M, Riggins GJ, Hann CL, Gallia GL.

J Neurosurg. 2012 Apr;116(4):801-9. doi: 10.3171/2011.12.JNS111123. Epub 2012 Jan 27.


Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo.

Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, Hann CL, Rudin CM.

Mol Cancer Res. 2011 Dec;9(12):1746-54. doi: 10.1158/1541-7786.MCR-11-0286. Epub 2011 Oct 12.


Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells.

Webster MR, Zhao M, Rudek MA, Hann CL, Freel Meyers CL.

J Med Chem. 2011 Oct 13;54(19):6647-56. doi: 10.1021/jm200521a. Epub 2011 Sep 9.


Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Rudin CM, Poirier JT, Senzer NN, Stephenson J Jr, Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL.

Clin Cancer Res. 2011 Feb 15;17(4):888-95. doi: 10.1158/1078-0432.CCR-10-1706. Epub 2011 Feb 8.


Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD.

Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7.


Glioblastoma multiforme in the Muir-Torre syndrome.

Binder ZA, Johnson MW, Joshi A, Hann CL, Griffin CA, Olivi A, Riggins GJ, Gallia GL.

Clin Neurol Neurosurg. 2011 Jun;113(5):411-5. doi: 10.1016/j.clineuro.2010.12.011. Epub 2011 Feb 1.


Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM.

J Clin Oncol. 2011 Mar 1;29(7):909-16. doi: 10.1200/JCO.2010.31.6208. Epub 2011 Jan 31.


Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.

Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA.

J Neurooncol. 2010 Apr;97(2):241-5. doi: 10.1007/s11060-009-0008-0. Epub 2009 Sep 19.


Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ.

Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.


Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2.


Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA.

N Engl J Med. 2009 Sep 17;361(12):1173-8. doi: 10.1056/NEJMoa0902903. Epub 2009 Sep 2.


Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.

Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, Vescovi AL, Brem H, Riggins GJ.

Mol Cancer Ther. 2009 Feb;8(2):386-93. doi: 10.1158/1535-7163.MCT-08-0680. Epub 2009 Feb 10.


Management of small-cell lung cancer: incremental changes but hope for the future.

Hann CL, Rudin CM.

Oncology (Williston Park). 2008 Nov 30;22(13):1486-92. Review.


Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.

Norgard NB, Saya S, Hann CL, Hennebry TA, Schechter E, Dale GL.

J Cardiovasc Pharmacol. 2008 Dec;52(6):536-9. doi: 10.1097/FJC.0b013e3181907390.


Cangrelor attenuates coated-platelet formation.

Norgard NB, Hann CL, Dale GL.

Clin Appl Thromb Hemost. 2009 Mar-Apr;15(2):177-82. doi: 10.1177/1076029608321437. Epub 2008 Sep 15.


Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.

Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM.

Cancer Res. 2008 Apr 1;68(7):2321-8. doi: 10.1158/0008-5472.CAN-07-5031.


Novel systemic therapies for small cell lung cancer.

Rudin CM, Hann CL, Peacock CD, Watkins DN.

J Natl Compr Canc Netw. 2008 Mar;6(3):315-22.


"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".

Hann CL, Brahmer JR.

Curr Treat Options Oncol. 2007 Feb;8(1):28-37. Review.


Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.

Hann CL, Rudin CM.

Trends Mol Med. 2007 Apr;13(4):150-7. Epub 2007 Feb 26. Review.


Second-line Therapy for advanced non-small-cell lung cancer.

Hann CL, Brahmer JR.

Curr Oncol Rep. 2006 Jul;8(4):243-7. Review.


Synovial sarcoma of the frontal sinus. Case report.

Gallia GL, Sciubba DM, Hann CL, Raman SP, Westra WH, Tufaro AP, Olivi A.

J Neurosurg. 2005 Dec;103(6):1077-80. Review.


The role of vena caval filters in the management of venous thromboembolism.

Hann CL, Streiff MB.

Blood Rev. 2005 Jul;19(4):179-202. Review.


Images in clinical medicine. Toxic neutrophils in Streptococcus pneumoniae sepsis.

Hann CL, Schmidt EP.

N Engl J Med. 2004 Dec 16;351(25):2636. No abstract available.


Drug-induced stabilization of covalent DNA topoisomerase I-DNA intermediates. DNA cleavage assays.

Fiorani P, Hann CL, Benedetti P, Bjornsti MA.

Methods Mol Biol. 2001;95:291-301. No abstract available.


Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.

Hann CL, Carlberg AL, Bjornsti MA.

J Biol Chem. 1998 Nov 20;273(47):31519-27.


Supplemental Content

Support Center